Hormonal
Semaglutide administration significantly reduces the incidence of atrial fibrillation by 42% compared to placebo in patients at high cardiovascular risk, primarily those with type 2 diabetes or obesity.
If you have type 2 diabetes or are overweight with high heart disease risk, ask your doctor about semaglutide. This medication has been shown to significantly lower your chance of developing atrial fibrillation, a common heart rhythm problem, regardless of whether you take it as a pill or a weekly injection. This benefit exists even if you do not have diabetes.
Semaglutide reduces the risk of AF by 42% (RR .58, 95% CI .40–.85)... Semaglutide significantly reduces the occurrence of incident AF by 42% as compared to placebo in individuals at high CV risk, mainly affected by type 2 diabetes mellitus.
Why this rating
Based on a systematic review and meta-analysis of 10 RCTs with low heterogeneity (I2 0%), though AF was a secondary safety outcome in the original trials.
Source
Glucagon‐like peptide‐1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta‐analysis
Andrea Saglietto et al. · European Journal of Clinical Investigation · 2024
DOI 10.1111/eci.14292
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →